Prostanoids, which promote vasodilation and reduce platelet aggregation, have been proposed as candidate therapies for intermittent claudication due to peripheral arterial disease (PAD). However, studies of these medications have yielded inconsistent results. This study tested the hypothesis that iloprost, an oral prostacyclin analogue, would improve walking distance and quality of life in patients with intermittent claudication. The study was a multi-center, randomized, double-blind, placebo-controlled trial comparing three doses of oral iloprost (50 μg, 100 μg, or 150 μg twice daily), pentoxifylline, or placebo in 430 patients with intermittent claudication. The primary outcome measure was improvement in absolute claudication distance (ACD) after 6 months. Secondary outcomes included initial claudication distance and quality of life assessment. Placebo increased ACD by 3.3%, and iloprost increased peak ACD by 7.7%, 8.8% and 11.2% at the 50 μg, 100 μg, and 150 μg twicedaily doses, respectively (all insignificant relative to placebo). Pentoxifylline increased ACD by 13.9% relative to placebo (p = 0.039). Neither iloprost nor pentoxifylline enhanced quality of life. These results indicate that oral iloprost is not effective in improving exercise performance or quality of life in patients with PAD who have intermittent claudication.
Introduction
Intermittent claudication is the cardinal symptom of peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis affecting over 5 million adults in the United States. 1 Intermittent claudication develops at an annual incidence of 5-7 per 1,000 persons over the age of 50. 2, 3 Both walking distance and speed are diminished in patients with claudication and as a result, quality of life is impaired by restrictions in normal daily activity. 4, 5 Only two drugs are approved by the Food and Drug Administration for the treatment of claudication: pentoxifylline, a methylxanthine derivative, and cilostazol, a phosphodiesterase III inhibitor. 6, 7 Iloprost is a stable prostacyclin analogue, the prin-cipal pharmacological effects of which include vasodilation, inhibition of platelet aggregation and adhesion, 9 and improved blood viscosity. 9 As such, it has potential value for the treatment of patients with intermittent claudication. Indeed, prior studies have shown that administration of iloprost and other vasodilator prostaglandins reduces ischemic pain and promotes ulcer healing in patients with critical limb ischemia. [10] [11] [12] However, more recent studies of parenterally administered prostanoids failed to demonstrate any improvement in amputation-free survival. 13 Studies of prostanoids in intermittent claudication have yielded inconsistent results. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Accordingly, the primary objective of this study was to determine the efficacy of oral iloprost in improving symptoms of intermittent claudication in patients with PAD.
Methods

Study design
This was a prospective, double-blind, randomized, placebo-controlled, parallel group study conducted from February 1998 to October 1999. A total of 430 patients at 32 centers participated in this trial. All participants gave written informed consent. Site monitoring, data collection, and data analysis were performed by Berlex Laboratories, Inc., the study's sponsor. The authors had full access to the data and the manuscript was written independently by the authors.
Eligibility
Men and women, 40 years of age or greater, with PAD and intermittent claudication (Fontaine Stage II) were eligible for participation. Participants were required to have stable claudication for at least 3 months prior to entry, despite standard care, which included cardiovascular risk factor modification and exercise training. Patients were eligible if they had an absolute claudication distance between 50 and 800 meters on a baseline eligibility exercise test. All patients were required to have an anklebrachial index (ABI) of ≤ 0.90 in the symptomatic leg. In addition, a greater than 20% fall in ABI within 1 minute following cessation of exercise served as confirmation of a diagnosis of PAD. In patients with non-compressible vessels (ABI > 1.50), the toe-brachial index (TBI) at rest had to be < 0.70.
After successful baseline screening, patients entered a 4-6 week single-blind placebo run-in phase. During this run-in phase, patients had to meet two requirements to qualify for randomization. First, the absolute claudication distance (ACD), measured by exercise treadmill test on two to three occasions at an interval of 7-14 days, had to be within 20% of the ACD measured at the previous exercise test. Patients could perform up to three tests to meet this requirement. Second, patients had to demonstrate compliance with the study drug (placebo) of between 80% and 120%.
Patients were excluded if they had ischemic rest pain, ulcers, or gangrene (Fontaine Stage III or IV), evidence of non-atherosclerotic PAD, and peripheral neuropathy that impaired walking ability. Additional exclusion criteria included a revascularization procedure for PAD within the preceding 3 months, sympathectomy within 6 months, type 1 diabetes mellitus, myocardial infarction or major cardiac surgery within 3 months, unstable angina, and heart failure. Patients receiving standard or low molecular weight heparin, warfarin in combination with aspirin, or any drug specific for the treatment of intermittent claudication were excluded. Patients receiving warfarin alone or aspirin alone were eligible.
Treatment assignment and dose adjustment
Eligible patients were randomized to one of five treatment groups of oral medication: placebo; ilo-prost 50 μg twice daily; iloprost 100 μg twice daily; iloprost 150 μg twice daily; or pentoxifylline 400 mg three times daily. All patients assigned to iloprost initially received 50 μg twice daily for 1 week. Thereafter, the dose was increased by 50 μg twice daily per week, until the maximal dose for each treatment assignment was achieved. Patients receiving pentoxifylline or placebo underwent mock titration (doses remained unchanged) during the first 2 weeks, to maintain blinding. Patients in all treatment groups were asked to take three capsules, administered orally, three times a day with meals. Patients assigned to pentoxifylline received one active treatment capsule and two placebo capsules with each meal. For the iloprost groups, all patients received a large placebo capsule to match the pentoxifylline capsule at each meal. Patients also received two additional capsules at each meal, either a 50 μg or 100 μg capsule, both together, or with matching placebo, according to the randomized dose of iloprost. Since active iloprost capsules were taken twice daily, patients assigned to iloprost received placebo capsules with one meal to ensure blinding. Therefore, in the iloprost groups, only the first two daily doses included active drug.
Patients returned for follow-up visits, including repeat treadmill testing, at 2 weeks, 1 month, 3 months, and 6 months following randomization.
Outcome measures
The primary efficacy measure was the change in ACD between baseline (using an average of the last two exercise tests during the run-in period) and 6 months. Walking distance was measured approximately 2 hours after the last dose of study medication. Secondary efficacy endpoints included the change in initial claudication distance (ICD) between baseline and 6 months, quality of life measurements, and rates of death, revascularization, and major amputation at 6 months.
A graded treadmill exercise test using a Gardner protocol was used to assess ACD and ICD. 26 On this protocol, treadmill speed remained at a constant 2 mph (3.2km/hr); the treadmill grade started at 0% and increased by 2% every 2 minutes. ICD was defined as distance walked at the onset of claudication. ACD was defined as the time when patients could walk no further on the treadmill because of claudication. The primary measure recorded during the treadmill test was walking time, which was subsequently converted into distance in meters. Since the treadmill test was graded, the meters walked during the first stage of the protocol were not equivalent in work performed to the subsequent stages. Thus, the ACD reflects peak exercise performance on the graded test.
Assessment of quality of life was performed at baseline and at 3 and 6 months after start of treatment using the Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36). The WIQ is a validated disease-specific instrument designed specifically for patients with intermittent claudication and assesses four domains of function: walking distance, walking speed, claudication pain severity, and stair climbing ability. 27, 28 The SF-36 is a generic, validated, widely used measure of healthrelated quality of life which contains 36 items measuring several health-related domains, including limitation in physical activity, social activity, mental health, bodily pain, vitality and general health perceptions. [29] [30] [31] 
Statistical analysis
The primary pre-specified analysis was the mean percent change from baseline to the end of 6 months of treatment in ACD (the primary efficacy variable) in the placebo group relative to the iloprost 100 μg twice daily group. The primary efficacy analysis was based on intention-to-treat (ITT). The ITT population consisted of all randomized patients who had a baseline treadmill measurement, received at least one dose of study drug, and had at least one follow-up treadmill measurement during the double-blind phase of this study. Statistical comparisons were made using the two-way analysis of covariance method (ANCOVA) and missing data were assigned using the last observation carried forward. Secondary analyses included individual comparisons between placebo and each dose of iloprost as well as pentoxifylline. No adjustment was made for multiple comparisons. Additional analyses compared differences among groups in percent improvement in the primary endpoint at 6 months using graded threshold criteria (25%, 25-50%, > 50% improvement compared to baseline). The Cochran-Mantel-Haenszel method based on rank (Van Elteren) was applied, stratified by baseline diabetic status. An analysis of the primary efficacy outcome measure was also performed on all randomized patients who completed the entire 6 months of treatment with study medication per protocol (perprotocol population). Secondary efficacy variables were also analyzed for the ITT and per-protocol populations.
The calculation of sample size was based on the comparison of placebo and iloprost (100 μg twice daily). It was assumed that improvement in ACD in the placebo group would be 20% and the detectable difference between the placebo group and the iloprost 100 μg twice daily group was estimated as 35% (which assumes a 55% improvement on drug). A sample of 80 patients per group (total sample size of 400 patients) was expected to provide 90% power to detect a difference of 35% (SD = 70%) between placebo and iloprost and mean percentage change from baseline and ACD at 6 months, based on a two-tailed t-test at alpha = 0.05 level.
Descriptive statistics included the mean number of patients and two-sided 95% confidence intervals. All statistical tests were two-tailed and performed at the 0.05 level of significance. Pairwise comparisons were made between the placebo and each of the three iloprost treatment groups to investigate the dose-response relationship. In addition, pairwise testing of pentoxifylline versus placebo and pentoxifylline versus each individual iloprost treatment group was performed. Pre-specified subgroup analyses included comparisons of age (< 65, ≥ 65 years), sex, race, smoking status, duration of PAD (< or > 12 months), prior intervention, use of antiplatelet drug during study, ACD at baseline (50-300 meters, ≥ 300-800 meters), and diabetic status.
Results
A total of 636 patients signed consent and were screened for meeting the entry criteria. Of these, 111 patients failed baseline screening. The remaining 525 patients met the inclusion criteria and were enrolled into the placebo run-in phase. Of these, 95 either failed to qualify for randomization or terminated their participation at the end of the run-in phase. The remaining 430 patients met their criteria for randomization and remained in the study; this group constituted the safety population. The baseline demographic characteristics of the randomized patients are provided in Table 1 according to treatment assignment. There were no statistically significant differences between the five treatment groups with respect to baseline characteristics. The mean age in all treatment groups was 67 years. Of the 430 patients, 349 (81.2%) were male and 81 (18.8%) were female. Use of aspirin was widespread and not different among the groups.
The ITT population consisted of 370 randomized patients who received at least one dose of study drug, and had a least one follow-up treadmill measurement during the double-blind phase of the study. Patients who did not qualify for the ITT population were principally those who stopped study medication during the first 2 to 4 weeks of the trial and did not perform a treadmill test even at the first month. The per-protocol patient population consisted of 214 randomized patients (50% of the 430 randomized patients) who completed the entire 6 months of treatment without a major protocol violation.
Primary endpoint
The mean percent changes in peak ACD at 6 months compared to baseline in the ITT population is illustrated in Figure 1 . Placebo-treated patients had only a minimal increase in ACD at 6 months compared to baseline (3.3%), while the iloprost 100 μg twice-daily dose increased ACD by 8.8% (the primary outcome). Iloprost increased ACD by 7.7% and 11.2% at the 50 μg and 150 μg twicedaily doses, respectively. None of the percentage increases (relative to baseline) in any of the iloprost groups was statistically significant compared to placebo.
Secondary endpoint
The additional ITT analysis of the primary efficacy measure based on the response at 6 months showed no statistically significant differences between the treatment groups with respect to the proportion of patients who achieved < 25%, 25-50%, and > 50% increases in ACD from baseline. Three-quarters (73-80%) of patients in all treatment groups had < 25% improvement in ACD over time.
Among the per-protocol population, the mean percent change in ACD for the placebo group was 3.2%. Of the patients randomized to iloprost, the mean percent change in ACD was 7.1%, 13.7% and 25.7% for the 50 μg, 100 μg, and 150 μg twice-daily groups, respectively. Of these, the iloprost 150 μg twice daily appeared to be significantly better than placebo (p = 0.041). However, further inspection revealed that the favorable change in mean value in this group was attributable to one patient who had a 270% improvement in ACD. Excluding this patient from the analysis, the mean percent change in ACD was 16.8% compared to placebo (p = 0.12). The mean percent change in ACD for the pentoxifylline group was 16.2% compared to placebo (p = 0.053).
Subgroup analyses were performed for the primary efficacy endpoint for various demographic variables including age, sex, race, smoking status, diabetic status, baseline ACD, duration of PAD, previous interventional therapy for PAD, and use of an antiplatelet agent. Among patients with a baseline ACD of ≥ 300 but < 800 meters, the mean percent increase in ACD at 6 months was significantly greater for iloprost 100 μg twice daily (14.5%, p = 0.007 vs placebo) and for pentoxifylline (12.9%, p = 0.011 vs placebo) than for placebo (-4.1%). Patients receiving pentoxifylline also had Mean percent change from baseline in peak absolute claudication distance (ACD) in the intentionto-treat population. Statistical comparison was made using the analysis of covariance (ANCOVA) comparing each treatment group to placebo. Data are shown as mean ± standard error. No significant differences were found between iloprost treatment groups and placebo. A statistically significant difference was found between pentoxifylline versus placebo (p = 0.039). significant improvements if they had a longer duration of PAD at baseline (> 12 months) (p = 0.042) or were taking concomitant antiplatelet therapy (p = 0.031). None of the other subgroup analyses demonstrated any signal of efficacy for iloprost. Pentoxifylline, serving as an active control, increased ACD by 13.9%, which was significantly greater than placebo (p = 0.039). There was no significant difference comparing any of the four active treatment groups with placebo in the mean percent change in ICD at 6 months. The increase in ICD in the placebo group was 21.2%. In the iloprost 50 μg, 100 μg, and 150 μg twice-daily groups, ICD increased by 24.0%, 28.9%, and 31.2%, respectively, and by 34.3% in the pentoxifylline group (all p = NS) ( Figure 2 ). Analysis of ICD at each interval time point showed only one significant treatment effect, occurring at 1 month in the pentoxifylline group compared to placebo (p = 0.006).
There were few patients in whom death, revascularization, or major amputation occurred during the 6-month double-blind phase. Rates of events were not numerically different between the treatment groups ( Table 2) .
Of the four domains assessed in the WIQ (i.e. walking distance, walking speed, claudication pain severity, and stair-climbing ability), differences were detected only in stair climbing. Patients taking iloprost 50 μg twice daily had an 11% increase in the stair-climbing score at 3 months relative to placebo (p = 0.03); those taking iloprost 150 μg twice daily had an increase in the stair-climbing score of 18% relative to placebo (p = 0.01) at 3 months and 16% relative to placebo (p = 0.03) at 6 months. There were no significant differences for the iloprost 100 μg twice daily group. Among those taking pentoxifylline, the stair-climbing score increased by 9% relative to placebo at 3 months (p = 0.04). Results of the SF-36 questionnaire failed to disclose any differences between treatment groups.
Adverse events (Table 3) The most frequently reported adverse events were headache, flushing, pain in the extremity, jaw pain, nausea, and diarrhea. Headache was reported in 44% of patients receiving iloprost 50 μg twice daily, in 64% of those receiving iloprost 100 μg bid, and in 67% of those receiving 150 μg twice daily compared with 19% of patients treated with pentoxifylline and 15% of patients treated with placebo. The frequency of flushing was comparable among the placebo (4%), pentoxifylline (2%) and iloprost 50 μg twice daily (5%) groups. However, flushing numerically increased in a dose-responsive manner in the patients receiving iloprost, reaching 23% in the 100 μg twice daily group and 31% in the 150 μg twice daily group. In addition to headaches and flushing, pain in the extremity, jaw pain, nausea, and diarrhea occurred more frequently in the iloprost groups compared with the other treatment groups. Mild dyspepsia occurred at approximately twice the frequency in patients receiving pentoxifylline (13%) compared with the other treatment groups.
Serious adverse events were defined as those that resulted in death, permanent substantial disability, inpatient hospitalization or prolongation of hospitalization or an adverse event that was lifethreatening or was a congenital anomaly, cancer or overdose. These occurred most commonly in individuals receiving iloprost 50 μg twice daily (14%) and pentoxifylline (14%), and were highest Figure 2 Mean percent change from baseline in peak initial claudication distance (ICD). Statistical comparison was made using the analysis of covariance (ANCOVA) comparing each treatment group to placebo. Data are shown as mean ± standard error. There were no significant differences among any of the treatment groups. in the placebo group (17%). There were no meaningful numerical differences among groups in any specific cardiovascular events (including angina, heart failure or myocardial infarction). The rate of adverse events leading to discontinuation of study medications was two to threefold higher in the iloprost groups than in placebo (31%, 57%, and 53% for each dose group respectively compared to 14% in the placebo group). The frequency of premature discontinuation among patients receiving pentoxifylline (15%) was similar to that of patients receiving placebo.
Discussion
Oral iloprost, taken for 6 months, failed to produce a significant improvement in either ACD or ICD compared to placebo in patients with intermittent claudication. Moreover, iloprost was poorly tolerated, principally due to side effects of headache and flushing, and was associated with high rates of discontinuation. Pentoxifylline served as an active control for comparison with the iloprost groups. The validity of these negative findings for iloprost is substantiated by the stability in ACD demonstrated by the placebo treatment group throughout the course of the study.
Vasodilator prostaglandins have pharmacological properties that underscore their potential efficacy in the treatment of symptomatic PAD. Drugs in this category include the prostacyclin (PGI-2) analogues, iloprost and beraprost, and the prostaglandin E1 (PGE-1), alprostadil. Prostacyclin induces peripheral vasodilation and inhibits platelet aggregation by activating adenylyl cyclase and increasing cyclic adenosine monophosphate (cAMP). 32 Daily intravenous administration of prostacyclin and PGE-1 for up to 28 days in patients with critical limb ischemia has been found to ameliorate manifestations of severe limb ischemia, [10] [11] [12] although the overall efficacy in these trials was often a Data are presented as percent of group and ratio compared to placebo (in parentheses). Adverse events reported are those that affected > 5% of any group with a ratio > 2.0 or < 0.5 in treatment groups compared to placebo. Serious adverse events and adverse events leading to discontinuation reported are those that affected > 1% of any group with a ratio > 2.0 or < 0.5 in treatment groups compared to placebo. b Serious adverse events were defined as any adverse event that resulted in death, permanent substantial disability, inpatient hospitalization or prolongation of existing inpatient hospitalization or an adverse event that was lifethreatening or was a congenital anomaly, cancer or overdose. c There were no meaningful numerical differences among groups in any specific cardiovascular events (including angina, congestive heart failure, and myocardial infarction).
modest and generally not sustained. Another recent study of an intravenous lipid-encapsulated PGE-1 prodrug, lipo-ecraprost, failed to show a difference in 6-month amputation rates in patients with critical limb ischemia. 13 For intermittent claudication, prostacyclin, PGE-1 and a PGE-1 prodrug, delivered intravenously for 4-8 weeks, have been reported to increase ACD and ICD. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Intravenous delivery of drugs, often for several hours, is neither feasible nor practical in patients with intermittent claudication, but an oral formulation of prostacyclin offers the possibility of symptomatic improvement without the inconvenience of intravenous therapy. In this study, 6 months of treatment with oral iloprost, at doses of 50 μg, 100 μg, and 150 μg twice daily, failed to improve either maximal or pain-free walking distance in patients with claudication. The study had approximately a 90% power to detect a 35% (i.e. clinically meaningful) improvement in ACD over placebo. The endpoint measures were acquired with extreme care and rigor as reflected in the placebo group, in whom ACD changed by only 3.3%. Thus, lack of efficacy cannot be attributed to instability or variability in the measure of ACD. The majority of patients in all treatment groups had less than 25% improvement in ACD. Similarly, iloprost conferred no benefit in ICD. Many patients experienced side effects, particularly headache and flushing, which contributed to a high dropout rate, with only 50% of the 430 randomized patients completing the full 6 months of treatment. Of these patients, the maximal walking distance increased modestly, but significantly, in the group that received iloprost 150 μg twice daily. For most patients, however, the high rate of intolerable side effects effectively negates the marginal benefit achieved in walking distance. These findings differ from those of a French study that reported that 6 months of treatment with oral beraprost, a PGI-2 analogue, improved both ICD and ACD. 24 A subsequent study found no benefit of oral beraprost compared with placebo on either ACD or ICD in patients with claudication, 25 supporting our conclusion.
Pentoxifylline is a xanthine derivative that increases cAMP levels by preventing its degradation via non-selective inhibition of phosphodiesterase. Its hemorrheologic properties are purported to include decreased plasma viscosity and improved erythrocyte and white cell flexibility, enabling greater blood flow, particularly in the microcirculation. [33] [34] [35] In several trials, pentoxifylline increased ACD by approximately 20% and ICD by approximately 30% compared to placebo, 4, 6, 36, 37 but studies published subsequent to the design and completion of our trial found no benefit 38 . In this study, pentoxifylline treatment resulted in a marginal, albeit sta-tistically significant, improvement in ACD that was 10% greater than placebo. Since the pentoxifyllineplacebo contrast was a secondary aim and was not adjusted for multiple comparisons, we cannot conclude any benefit from pentoxifylline, despite the significant p-value. Therefore, this study does not support the use of pentoxifylline for treatment of intermittent claudication, as the effect is not likely to represent a clinically meaningful change in walking ability, and there was no consistent improvement in quality of life. It does, however, validate the trial design as sufficiently sensitive to detect a difference in the primary outcome variable with an active compound compared to placebo.
Two validated questionnaires were utilized to assess quality of life in this trial. The WIQ, which is specific for patients with intermittent claudication, revealed a slight improvement in stairclimbing ability at 6 months in the iloprost 150 μg twice daily group, but no improvement in walking distance, walking speed or claudication pain severity. No improvement was detected by the SF-36 questionnaire. These findings are consistent with the lack of clinical improvement in walking distance observed in the iloprost groups.
Conclusions
Iloprost, when administered orally in doses of 50 to 150 μg twice daily for 6 months to patients with intermittent claudication, did not improve maximal walking distance or the distance walked to the onset of claudication. In addition, oral iloprost was associated with frequent side effects and was not well tolerated. On the basis of this study, neither iloprost nor pentoxifylline can be recommended as therapy for patients with intermittent claudication.
